COG Erwinase Use for Acute Lymphoblastic Leukemia (ALL) Treatment Under IND 290.

Trial Profile

COG Erwinase Use for Acute Lymphoblastic Leukemia (ALL) Treatment Under IND 290.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Asparaginase (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; T cell lymphoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms EMTP
  • Most Recent Events

    • 09 Jun 2010 New source identified and integrated (Vanderbilt-Ingram Cancer Center, VICCPED0711).
    • 21 Apr 2009 New source identified and integrated (Barbara Ann Karmanos Cancer Institute).
    • 21 Apr 2009 Additional lead trial investigator identified as reported by Barbara Ann Karmanos Cancer Institute.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top